Bacterial Infection Identification via Peritoneal Marker Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for bacterial infections, particularly in peritoneal dialysis patients, are delayed and lack specificity, leading to inadequate treatment and the development of antibiotic resistance, as they rely on traditional culture techniques that take days to weeks for results and often fail to identify causative organisms in 'culture-negative' peritonitis cases.
Innovation Solution
A method involving the analysis of peritoneal samples to determine the relative amounts of specific cellular and humoral markers such as Vδ2+ T cells, IL-10, IL-1β, TNF-α, CXCL10, and CD86 to differentiate between Gram-negative and Gram-positive bacterial infections, allowing for rapid identification and targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional culture techniques are used for pathogen identification, then microbiological confirmation is achieved, but significant time delay occurs (2 days to 2 months)
Solution Approach 1:
The patent replaces traditional mechanical culture techniques with mass spectrometry-based detection (MALDI-TOF). The system uses a rapid antigen detection assay that measures cellular and humoral markers in peritoneal samples, providing results within hours rather than days or weeks. This substitution of detection methodology eliminates the time-consuming culture phase while maintaining diagnostic accuracy through spectral analysis of bacterial proteins and host immune responses.
2Reliability
If broad-spectrum antibiotics are used to cover multiple possible pathogens, then treatment coverage is improved, but antibiotic resistance and C. difficile infection risk increase
Solution Approach 1:
The patent performs preliminary pathogen identification using mass spectrometry analysis of peritoneal samples before initiating antibiotic therapy. By detecting specific cellular markers (neutrophils, monocytes, T cells) and humoral markers (cytokines, chemokines) and comparing them against a database of known pathogen profiles, the system identifies the causative organism in advance. This preliminary diagnosis enables targeted antibiotic selection, preventing the need for broad-spectrum empiric therapy and thereby reducing the risk of antibiotic resistance and secondary infections like C. difficile.
3Measurement precision
If conventional culture techniques are used, then pathogen identification is attempted, but many cases remain culture-negative and cause remains unknown
Solution Approach 1:
The patent employs mass spectrometry-based detection that analyzes both cellular components (white blood cell types and counts) and humoral components (cytokines, chemokines, antibodies) in peritoneal samples simultaneously. This multi-parameter analysis approach detects pathogen-specific immune responses even when the organism cannot be cultured. The system compares the measured marker profile against a comprehensive database to identify the causative pathogen, thereby resolving culture-negative cases that would otherwise remain diagnostically uncertain.
4Productivity
If rapid antigen detection assays are used, then diagnostic speed is improved, but complexity of the assay increases
Solution Approach 1:
The patent employs a universal mass spectrometry platform (MALDI-TOF) that can detect and analyze multiple types of markers simultaneously - cellular markers (neutrophils, monocytes, lymphocytes), humoral markers (cytokines, chemokines, antibodies), and pathogen-specific proteins. This single multi-functional instrument replaces the need for multiple separate assays, thereby maintaining rapid diagnostic speed while managing complexity through platform integration. The system processes peritoneal samples through a standardized workflow that yields comprehensive diagnostic information in one run.
Data Source
AI summary
Method for identifying a bacterial infection The present application concerns a method for identifying the nature of a bacterial infection from a peritoneal sample, in particular, whether it is a Gram-negative or Gram-positive infection, based upon the determination of one or more cellular and/or humoral markers in a sample.